Pharmaceutical composition promoting defecation

Abstract

The present invention provides a medicament having a gentle but strong defecation-promoting action without causing diarrhea. That is, it provides a defecation-promoting agent comprising a compound having an adenosine A 2 receptor antagonism, preferably an adenosine A 2b receptor antagonism, or a salt thereof.

1 . A defecation-promoting agent comprising a compound having an adenosine A 2  receptor antagonism or a salt thereof.  
   
   
       2 . A defecation-promoting agent comprising a compound having an adenosine A 2b  receptor antagonism or a salt thereof.  
   
   
       3 . The defecation-promoting agent according to  claim 1  or  2 , which is for treating, preventing or improving a symptom where defecation is difficult and/or rare.  
   
   
       4 . The defecation-promoting agent according to  claim 1  or  2 , which is an agent for treating, preventing or improving constipation.  
   
   
       5 . The defecation-promoting agent according to  claim 1  or  2 , which is an agent for treating, preventing or improving functional constipation.  
   
   
       6 . The defecation-promoting agent according to  claim 5 , wherein the functional constipation is spastic constipation or atonic constipation.  
   
   
       7 . The defecation-promoting agent according to  claim 1  or  2 , which is an agent for treating, preventing or improving irritable bowel syndrome or constipation accompanying irritable bowel syndrome.  
   
   
       8 . The defecation-promoting agent according to  claim 1  or  2 , which is an agent for treating, preventing or improving organic constipation, constipation accompanying enteroparalytic ileus, constipation accompanying congenital digestive tract dysfunction or constipation accompanying ileus.  
   
   
       9 . The defecation-promoting agent according to  claim 1  or  2 , which is for evacuating intestinal tracts at the time of examination of digestive tracts or before and after an operation.  
   
   
       10 . The defecation-promoting agent according to  claim 1  or  2 , wherein the compound is at least one compound selected from 2-amino-4-(2-furyl)-5-(4-pyridyl)pyrimidine, 3-n-propylxanthine, theophylline, caffeine, 1,3-dipropylxanthine, enprophylline, 1-methyl-3-isobutylxanthine, paraxanthine, 8-phenyltheophylline, 1,3-diethyl-8-phenylxanthine, 8-[4-[[[[(2-aminoethyl)amino]carbonyl]methyl]oxy]phenyl]-1,3-dipropylxanthine, 8-[4-[[[methyl-(2-dimethylaminoethyl)-amino]sulfonyl]phenyl]-1,3-dipropylxanthine, 1,3-dimethyl-8-(p-sulfophenyl)xanthine and 1,3-dipropyl-8-(p-sulfophenyl)xanthine.  
   
   
       11 . Use of a compound having an adenosine A 2  receptor antagonism or a salt thereof for producing a defecation-promoting agent.  
   
   
       12 . Use of a compound having an adenosine A 2b  receptor antagonism or a salt thereof for producing a defecation-promoting agent.  
   
   
       13 . Use of an adenosine A 2b  receptor antagonist for a pharmaceutical preparation for treating, preventing or improving constipation.  
   
   
       14 . A method for promotion of defecation, by administering a pharmacologically effective amount of a compound having an adenosine A 2  receptor antagonism or a salt thereof to a patient.  
   
   
       15 . A method for promotion of defecation, by administering a pharmacologically effective amount of a compound having an adenosine A 2b  receptor antagonism or a salt thereof to a patient.  
   
   
       16 . A method for treating, preventing or improving constipation, by administering a pharmacologically effective amount of a compound having an adenosine A 2b  receptor antagonism or a salt thereof to a patient.